Hailey Borg
Healthcare: Biotech and Pharma Innovation
Expected Outperformers: Moderna, Vertex Pharmaceuticals, BioNTech
Why: Expanding mRNA applications in cancer and personalised medicine. Vertex is a leader in cystic fibrosis treatments with a promising gene-editing pipeline.
Wildcard: CRISPR Therapeutics
Why: Gene therapy approvals could catalyse exponential growth for this early-stage biotech company.
Financial Services: The DeFi and Payment Revolution
Expected Outperformers: Visa, Mastercard, PayPal
Why: Expansion into digital currencies and a robust consumer spending recovery.
Wildcard: Block (formerly Square)
Why: Its blockchain payment solutions and small business services offer strong growth potential.
Industrial Automation and Robotics
Expected Outperformers: ABB, Fanuc Corporation, Rockwell Automation
Why: Labour shortages and rising costs will drive demand for automation in manufacturing and logistics.
Wildcard: UiPath
Why: Its market position in robotic process automation (RPA) for enterprise clients ensures significant growth opportunities.
By identifying these outperformers and risks, investors can better navigate 2025’s complexities and capitalise on emerging opportunities. Let me know if you’d like a deep dive into any specific company or sector!
You Might Also Like
Latest Article
Unsolicited PR Advice Alert #3: How To Win Over Journalists
Stop sending newsrooms coasters, novelty espresso cups, or stress balls with your logo on them. Instead, give journalists what they actually need: exclusive stories, clear answers with usable quotes, and solid data. And, if you really want them to like you, send a bottle of scotch at Christmas. Honestly, it’s that simple. … Continued
|
19 April 2025
Written by Ivan Martin
What If Trump’s Tariffs Tear Down the System — And That’s A Good Thing?
|
19 April 2025
Written by Hailey Borg
Small but Mighty: Why SMEs Will Shape Malta’s Economic Future
|
19 April 2025
Written by Hailey Borg
